These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
147 related items for PubMed ID: 29154112
1. Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal women - The Danish Diet, Cancer and Health cohort. Kyrø C, Hansen L, Frederiksen K, Nørskov NP, Bach Knudsen KE, Eriksen AK, Holm M, Tjønneland A, Olsen A. Clin Nutr; 2018 Dec; 37(6 Pt A):2217-2225. PubMed ID: 29154112 [Abstract] [Full Text] [Related]
3. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjønneland A. Breast Cancer Res Treat; 2011 Aug; 128(3):883-9. PubMed ID: 21340481 [Abstract] [Full Text] [Related]
5. Prediagnosis plasma concentrations of enterolactone and survival after colorectal cancer: the Danish Diet, Cancer and Health cohort. Kyrø C, Frederiksen K, Holm M, Nørskov NP, Knudsen KEB, Overvad K, Tjønneland A, Olsen A. Br J Nutr; 2019 Sep 14; 122(5):552-563. PubMed ID: 30173678 [Abstract] [Full Text] [Related]
6. Plasma enterolactone and incidence of endometrial cancer in a case-cohort study of Danish women. Aarestrup J, Kyrø C, Knudsen KE, Weiderpass E, Christensen J, Kristensen M, Würtz AM, Johnsen NF, Overvad K, Tjønneland A, Olsen A. Br J Nutr; 2013 Jun 28; 109(12):2269-75. PubMed ID: 23114205 [Abstract] [Full Text] [Related]
7. Pre-diagnostic plasma enterolactone concentrations are associated with lower mortality among individuals with type 2 diabetes: a case-cohort study in the Danish Diet, Cancer and Health cohort. Eriksen AK, Kyrø C, Nørskov NP, Frederiksen K, Bach Knudsen KE, Overvad K, Landberg R, Tjønneland A, Olsen A. Diabetologia; 2019 Jun 28; 62(6):959-969. PubMed ID: 30963187 [Abstract] [Full Text] [Related]
8. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Piller R, Chang-Claude J, Linseisen J. Eur J Cancer Prev; 2006 Jun 28; 15(3):225-32. PubMed ID: 16679865 [Abstract] [Full Text] [Related]
9. Serum enterolactone and prognosis of postmenopausal breast cancer. Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J. J Clin Oncol; 2011 Oct 01; 29(28):3730-8. PubMed ID: 21900115 [Abstract] [Full Text] [Related]
10. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers. Jaskulski S, Jung AY, Behrens S, Johnson T, Kaaks R, Thöne K, Flesch-Janys D, Sookthai D, Chang-Claude J. Int J Cancer; 2018 Dec 01; 143(11):2698-2708. PubMed ID: 29974464 [Abstract] [Full Text] [Related]
11. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Guglielmini P, Rubagotti A, Boccardo F. Breast Cancer Res Treat; 2012 Apr 01; 132(2):661-8. PubMed ID: 22094938 [Abstract] [Full Text] [Related]
12. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II. Xie J, Tworoger SS, Franke AA, Terry KL, Rice MS, Rosner BA, Willett WC, Hankinson SE, Eliassen AH. Breast Cancer Res Treat; 2013 Jun 01; 139(3):801-9. PubMed ID: 23760859 [Abstract] [Full Text] [Related]
13. Plasma enterolactone and risk of colon and rectal cancer in a case-cohort study of Danish men and women. Johnsen NF, Olsen A, Thomsen BL, Christensen J, Egeberg R, Bach Knudsen KE, Loft S, Overvad K, Tjønneland A. Cancer Causes Control; 2010 Jan 01; 21(1):153-62. PubMed ID: 19844797 [Abstract] [Full Text] [Related]
14. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, Møller S, Tjønneland A. Cancer Epidemiol Biomarkers Prev; 2004 Dec 01; 13(12):2084-9. PubMed ID: 15598765 [Abstract] [Full Text] [Related]
15. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, Kaaks R, Chang-Claude J. Int J Cancer; 2012 Mar 15; 130(6):1401-10. PubMed ID: 21544804 [Abstract] [Full Text] [Related]
16. Genistein and enterolactone in relation to Ki-67 expression and HER2 status in postmenopausal breast cancer patients. Jaskulski S, Jung AY, Rudolph A, Johnson T, Thöne K, Herpel E, Sinn P, Chang-Claude J. Mol Nutr Food Res; 2017 Nov 15; 61(11):. PubMed ID: 28734033 [Abstract] [Full Text] [Related]
17. Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Stattin P, Bylund A, Biessy C, Kaaks R, Hallmans G, Adlercreutz H. Cancer Causes Control; 2004 Dec 15; 15(10):1095-102. PubMed ID: 15801493 [Abstract] [Full Text] [Related]
18. Prediagnostic enterolactone concentrations and mortality among Danish men diagnosed with prostate cancer. Eriksen AK, Kyrø C, Nørskov N, Bolvig AK, Christensen J, Tjønneland A, Overvad K, Landberg R, Olsen A. Eur J Clin Nutr; 2017 Oct 15; 71(10):1235-1240. PubMed ID: 28378849 [Abstract] [Full Text] [Related]
19. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H. Cancer Epidemiol Biomarkers Prev; 2001 Apr 15; 10(4):339-44. PubMed ID: 11319174 [Abstract] [Full Text] [Related]
20. An incident case-referent study on plasma enterolactone and breast cancer risk. Hultén K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G. Eur J Nutr; 2002 Aug 15; 41(4):168-76. PubMed ID: 12242585 [Abstract] [Full Text] [Related] Page: [Next] [New Search]